Elisigen

Neuracle Genetics is a South Korean biotechnology company established in May 2018, specializing in the development of Adeno-Associated Virus (AAV) vector-based gene therapies. The company focuses on creating treatments for neurodegenerative disorders, ophthalmic diseases, and other intractable rare diseases. Headquartered in Seoul and founded by CEO Jongmuk Kim, the firm aims to address conditions with significant unmet medical needs.

The company's business model is centered on the research, development, and eventual commercialization of its proprietary gene therapy candidates. Its core technology is an AAV vector engineering platform designed for high-efficiency gene delivery and expression. A key aspect of this technology is its ability to achieve therapeutic effects at lower doses, potentially reducing side effects and production costs. Neuracle Genetics operates in the global gene therapy market, a sector experiencing significant growth driven by advances in gene-editing tools and the rising prevalence of genetic disorders. The company establishes strategic partnerships for development and manufacturing; a significant collaboration is with Reyon Pharmaceutical for the co-development and exclusive manufacturing of its lead product, NG101.

The pipeline includes several candidates, with NG101 being the most advanced. NG101 is a gene therapy for wet Age-related Macular Degeneration (wAMD) that delivers the gene for aflibercept, the active ingredient in the standard treatment Eylea. This therapy is designed to provide long-term effects from a single injection, reducing the treatment burden for patients who currently require frequent intraocular injections. NG101 has received Fast Track Designation from the U.S. FDA and is undergoing Phase 1/2a clinical trials in the U.S. and Canada. Another key pipeline candidate is NG201, which targets neuropathic pain.

Since its founding, Neuracle Genetics has secured significant funding through several investment rounds, including a seed round in 2018, a Series A in 2019, and a Series B in 2021, attracting investors such as Reyon Pharmaceutical, DAYLI Partners, and Partners Investment.

Keywords: AAV gene therapy, neurodegenerative disorders, rare diseases, wet age-related macular degeneration, drug discovery, biotechnology, AAV vector engineering, clinical trials, neuropathic pain, ophthalmic diseases, NG101, single-injection treatment, cell and gene therapy, Seoul, life sciences, venture capital, biologics manufacturing